Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647179 | 0.88 | NAMPT (0.40) | ROCK2NAMPTEIF4A3PDE2AKDM4E | |
| SCHEMBL17452667 | 0.88 | ROCK2 (0.39) | ROCK2NAMPTEIF4A3PDE2AJAK1 | |
| SCHEMBL17454359 | 0.85 | ROCK2 (0.40) | ROCK2EIF4A3ALDH1A1JAK1JAK3 | |
| SCHEMBL17437914 | 0.84 | ROCK2 (0.39) | ROCK2NAMPTEIF4A3JAK1JAK3 | |
| SCHEMBL21947212 | 0.80 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL20229599 | 0.77 | SMO (0.39) | ROCK2EIF4A3PDE2ASMOKDM4E | |
| SCHEMBL23888960 | 0.76 | NAMPT (0.43) | ROCK2NAMPTEIF4A3PDE2AJAK1 | |
| SCHEMBL24247709 | 0.74 | EIF4A3 (0.37) | ROCK2NAMPTEIF4A3 | |
| SCHEMBL23889176 | 0.73 | P2RY12 (0.36) | ROCK2EIF4A3ACACB | |
| SCHEMBL20647178 | 0.71 | HIF1A (0.38) | ROCK2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885NAMPT 1390/4885EIF4A3 4527/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885NAMPT 1390/4885EIF4A3 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.